With the government planning to release a drug price reform plan that includes a fair value compensation plan for innovative new drugs as early as next month, attention is focused on whether the reform will include a preferential measure for new drugs that demonstrate non-inferiority.

This is because most of the new drugs that domestic pharmaceutical companies have successfully developed are new drugs that have demonstrated non-inferiority to existing drugs.

Until now, non-inferior new drugs have been listed at a price below the weighted average of its alternatives. Therefore, the industry has been criticizing how the prices do not properly reflect the innovativeness of the developed new dru